From: Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy
Testosterone deficiency (n = 72) | Without testosterone deficiency (n = 173) | p value | |
---|---|---|---|
Weight [kg, median (IQR)] | 76.3 (25.9) | 71.3 (16.2) | 0.857a |
Height [cm, median (IQR)] | 171.0 (8.0) | 169.0 (7.5) | 0.204a |
BMI [(kg/m2), median (IQR)] | 26.5 (16.8) | 25.2 (5.4) | 0.160a |
Underweight [n (%)] | 5 (7.0) | 6 (3.6) | 0.028b/0.155c |
Normal weight [n (%)] | 26 (36.3) | 78 (46.2) | |
Overweight [n (%)] | 23 (32.4) | 67 (39.6) | |
Obesity [n (%)] | 17 (23.9) | 18 (10.7) | |
Neck circumference [cm, median (IQR)] | 40.0 (4.8) | 39.0 (3.0) | 0.196a |
Upper-arm circumference [cm, median (IQR)] | 28.3 (3.8) | 28.0 (3.8) | 0.197a |
Abdominal circumference [cm, median (IQR)] | 98.0 (13.8) | 93.0 (8.6) | 0.492a |
Waist circumference [cm, median (IQR)] | 99.5 (19.8) | 93.0 (13.5) | 0.030a |
Hip circumference [cm, median (IQR)] | 47.0 (6.0) | 47.5 (6.0) | 0.906a |
Metabolic syndrome [n (%)] | 33 (45.8) | 69 (39.9) | 0.390b |
Blood pressure [n (%)] | 30 (41.7) | 69 (40.1 %) | 0.822b |
Systolic blood pressure [median (IQR)] | 133.5 (40.0) | 130.0 (30.0) | 0.007a |
Diastolic blood pressure [median (IQR)] | 79.0 (25.0) | 80.0 (15.0) | 0.756a |
Smoking history [n (%)] | |||
Current | 21 (30.4) | 72 (42.6) | 0.127b |
Former | 25 (36.2) | 42 (24.9) | |
Never | 23 (33.3) | 55 (32.5) | |
Alcohol consumption [n (%)] | 41 (59.4) | 77 (45.6) | 0.052b |
Total cholesterol [mg/dL, median (IQR)] | 210.0 (69.0) | 221.0 (70.5) | 0.668a |
LDL cholesterol [mg/dL, median (IQR)] | 129.0 (37.0) | 129.0 (72.8) | 0.573a |
HDL cholesterol [mg/dL, median (IQR)] | 43.5 (13.3) | 42.5 (13.3) | 0.125a |
Triglycerides [mg/dL, median (IQR)] | 215.0 (215.3) | 218.0 (162.0) | 0.631a |
HbA1c [%, median (IQR)] | 5.5 (1.7) | 5.3 (1.0) | 0.016a |
Total testosterone [ng/mL, median (IQR)] | 2.6 (2.6) | 5.9 (2.7) | <0.001a |
Free testosterone [ng/dL, median (IQR)] | 5.2 (1.5) | 9.1 (3.6) | <0.001a |
SHBG [nmol/L, median (IQR)] | 35.2 (44.6) | 46.6 (29.6) | 0.083a |
LH [mIU/mL, median (IQR)] | 5.0 (4.9) | 5.2 (3.2) | 0.001a |
FSH [mIU/mL, median (IQR)] | 6.7 (7.1) | 5.1 (4.1) | <0.001a |
FRS [median (IQR)] | 13.0 (5.0) | 12.0 (6.0) | 0.004a |
<10 [n (%)] | 16 (22.2) | 66 (38.2) | 0.008b/0.003c |
10–20 [n (%)] | 48 (66.7) | 101 (58.4) | |
>20 [n (%)] | 8 (11.1) | 6 (3.5) | |
10-Year ASCVD risk [%, median (IQR)] | 7.1 (6.5) | 6.8 (8.3) | 0.002a |
Lifetime ASCVD risk [n (%)] | |||
<40 % | 4 (10.0) | 11 (8.0) | 0.789b |
40–50 % | 22 (55.0) | 84 (60.9) | |
>50 % | 14 (35.0) | 43 (31.2) | |
Lipodistrophy [n (%)] | 39 (56.5) | 96 (58.5) | 0.776b |
Waist circumference (>102 cm) [n(%)] | 23 (31.9) | 30 (17.3) | 0.011b |
No lipodystrophy [n (%)] | 20 (27.8) | 59 (34.3) | 0.321b |
Isolated central fat accumulation [n (%)] | 13 (18.1) | 13 (7.5) | 0.015b |
Isolated lipoatrophy [n (%)] | 29 (40.3) | 83 (48.3) | 0.254b |
Mixed forms of lipodystrophy [n (%)] | 10 (13.9) | 17 (9.8) | 0.355b |